Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 25;18(1):16.
doi: 10.1186/s12984-021-00818-2.

A review of movement disorders in chemotherapy-induced neurotoxicity

Affiliations
Review

A review of movement disorders in chemotherapy-induced neurotoxicity

Allison B Wang et al. J Neuroeng Rehabil. .

Abstract

Chemotherapy agents used in the standard treatments for many types of cancer are neurotoxic and can lead to lasting sensory and motor symptoms that compromise day-to-day movement functions in cancer survivors. To date, the details of movement disorders associated with chemotherapy are known largely through self-reported symptoms and functional limitations. There are few quantitative studies of specific movement deficits, limiting our understanding of dysfunction, as well as effective assessments and interventions. The aim of this narrative review is to consolidate the current understanding of sensorimotor disabilities based on quantitative measures in cancer survivors who received chemotherapy. We performed literature searches on PubMed and found 32 relevant movement studies. We categorized these studies into three themes based on the movement deficits investigated: (1) balance and postural control; (2) gait function; (3) upper limb function. This literature suggests that cancer survivors have increased postural sway, more conservative gait patterns, and suboptimal hand function compared to healthy individuals. More studies are needed that use objective measures of sensorimotor function to better characterize movement disabilities and investigate the underlying causes, as required for developing targeted assessments and interventions. By updating our understanding of movement impairments in this population, we identify significant gaps in knowledge that will help guide the direction of future research.

Keywords: CIPN; Cancer; Chemotherapy; Neuropathy; Sensorimotor dysfunction.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of article selection process

References

    1. Zajaczkowska R, Kocot-Kepska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. doi: 10.3390/ijms20061451. - DOI - PMC - PubMed
    1. Housley SN, Nardelli P, Powers RK, Rich MM, Cope TC. Chronic defects in intraspinal mechanisms of spike encoding by spinal motoneurons following chemotherapy. Exp Neurol. 2020;331:113354. doi: 10.1016/j.expneurol.2020.113354. - DOI - PMC - PubMed
    1. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol. 2009;63(5):761–767. doi: 10.1007/s00280-008-0876-6. - DOI - PubMed
    1. Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies—a growing problem for patients and health care providers. Brain Behav. 2017;7(1):e00558. doi: 10.1002/brb3.558. - DOI - PMC - PubMed
    1. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77. doi: 10.1016/j.critrevonc.2011.04.012. - DOI - PubMed

Publication types

MeSH terms

Substances